Carbonate apatite nanoparticles carry siRNA(s) targeting growth factor receptor genes egfr1 and erbb2 to regress mouse breast tumor

References

• Allen LF, Lenehan PF, Eiseman IA, et al. (2002). Potential benefits of the irreversible pan-erbB inhibitor, CI-1033, in the treatment of breast cancer. Semin Oncol 29:11–21.
   PubMed Web of Science ®Google Scholar
• Butt AJ, Firth SM, Baxter RC. (1999). The IGF axis and programmed cell death. Immunol Cell Biol 77:256–62.
   PubMed Web of Science ®Google Scholar
• Campiglio M, Locatelli A, Olgiati C, et al. (2004). Inhibition of proliferation and induction of apoptosis in breast cancer cells by the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor ZD1839 (‘Iressa’) is independent of EGFR expression level. J Cell Physiol 198:259–68.
   PubMed Web of Science ®Google Scholar
• Castanotto D, Sakurai K, Lingeman R, et al. (2007). Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC. Nucleic Acids Res 35:5154–64.
   PubMed Web of Science ®Google Scholar
• Chong YM, Colston K, Jiang WG, et al. (2006). The relationship between the insulin-like growth factor-1 system and the oestrogen metabolising enzymes in breast cancer tissue and its adjacent non-cancerous tissue. Breast Cancer Res Treat 99:275–88.
   PubMed Web of Science ®Google Scholar
• Chua MJ, Tiash S, Fatemian T, et al. (2013). Carbonate apatite-facilitated intracellular delivery of c-ROS1 small interfering RNA sensitises MCF-7 breast cancer cells to cisplatin and paclitaxel. OA Cancer 1:1–9.
   Google Scholar
• Dent P, Reardon DB, Park JS, et al. (1999). Radiation-induced release of transforming growth factor alpha activates the epidermal growth factor receptor and mitogen-activated protein kinase pathway in carcinoma cells, leading to increased proliferation and protection from radiation-induced cell death. Mol Biol Cell 10:2493–506.
   PubMed Web of Science ®Google Scholar
• Di Fiore PP, Pierce JH, Kraus MH, et al. (1987). erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178–82.
   PubMed Web of Science ®Google Scholar
• Gao S, Dagnaes-Hansen F, Nielsen EJ, et al. (2009). The effect of chemical modification and nanoparticle formulation on stability and biodistribution of siRNA in mice. Mol Ther 17:1225–33.
   PubMed Web of Science ®Google Scholar
• Gee JM, Robertson JF, Gutteridge E, et al. (2005). Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer. Endocr Relat Cancer 12:S99–S111.
   PubMed Web of Science ®Google Scholar
• Grimm D, Streetz KL, Jopling CL, et al. (2006). Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways. Nature 441:537–41.
   PubMed Web of Science ®Google Scholar
• Guy CT, Cardiff RD, Muller WJ. (1996). Activated neu induces rapid tumor progression. J Biol Chem 271:7673–8.
   PubMed Web of Science ®Google Scholar
• Guy CT, Webster MA, Schaller M, et al. (1992). Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA89:10578–82.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Shin DM. (2002). Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer 94:1593–611.
   PubMed Web of Science ®Google Scholar
• Hossain S, Stanislaus A, Chua MJ, et al. (2010). Carbonate apatite-facilitated intracellularly delivered siRNA for efficient knockdown of functional genes. J Control Release 147:101–8.
   PubMed Web of Science ®Google Scholar
• Hurtado A, Holmes KA, Geistlinger TR, et al. (2008). Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature 456:663–6.
   PubMed Web of Science ®Google Scholar
• Hutvagner G, Simard MJ, Mello CC, Zamore PD. (2004). Sequence-specific inhibition of small RNA function. PLoS Biol 2:E98
   PubMed Web of Science ®Google Scholar
• Kaulfuss S, Burfeind P, Gaedcke J, Scharf JG. (2009). Dual silencing of insulin-like growth factor-I receptor and epidermal growth factor receptor in colorectal cancer cells is associated with decreased proliferation and enhanced apoptosis. Mol Cancer Ther 8:821–33.
   PubMed Web of Science ®Google Scholar
• Khan AA, Betel D, Miller ML, et al. (2009). Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs. Nat Biotechnol 27:549–55.
   PubMed Web of Science ®Google Scholar
• Klijn JG, Berns PM, Schmitz PI, Foekens JA. (1992). The clinical significance of epidermal growth factor receptor (EGF-R) in human breast cancer: a review on 5232 patients. Endocr Rev 13:3–17.
   PubMed Web of Science ®Google Scholar
• Knowlden JM, Hutcheson IR, Jones HE, et al. (2003). Elevated levels of epidermal growth factor receptor/c-erbB2 heterodimers mediate an autocrine growth regulatory pathway in tamoxifen-resistant MCF-7 cells. Endocrinology 144:1032–44.
   PubMed Web of Science ®Google Scholar
• Koller E, Propp S, Murray H, et al. (2006). Competition for RISC binding predicts in vitro potency of siRNA. Nucleic Acids Res 34:4467–76.
   PubMed Web of Science ®Google Scholar
• Kothari S, Cizeau J, McMillan-Ward E, et al. (2003). BNIP3 plays a role in hypoxic cell death in human epithelial cells that is inhibited by growth factors EGF and IGF. Oncogene 22:4734–44.
   PubMed Web of Science ®Google Scholar
• Kumar R, Mandal M, Lipton A, et al. (1996). Overexpression of HER2 modulates bcl-2, bcl-XL, and tamoxifen-induced apoptosis in human MCF-7 breast cancer cells. Clin Cancer Res 2:1215–19.
   PubMed Web of Science ®Google Scholar
• Kunnath AP, Kamaruzman NI, Chowdhury EH. (2014a). Nanoparticle-facilitated intratumoral delivery of Bcl-2/IGF-1R siRNAs and p53 gene synergistically inhibits tumor growth in immunocompetent mice. J Nanomed Nanotechnol S9:001.
   Google Scholar
• Kunnath AP, Tiash S, Fatemian T, et al. (2014b). Intracellular delivery of ERBB2 siRNA and p53 gene synergistically inhibits the growth of established tumor in an immunocompetent mouse. J Cancer Sci Ther 6:99–104.
   Google Scholar
• Layzer JM, McCaffrey AP, Tanner AK, et al. (2004). In vivo activity of nuclease-resistant siRNAs. RNA 10:766–71.
   PubMed Web of Science ®Google Scholar
• Morrissey DV, Lockridge JA, Shaw L, et al. (2005). Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 23:1002–7.
   PubMed Web of Science ®Google Scholar
• Nahta R, Hortobagyi GN, Esteva FJ. (2003). Growth factor receptors in breast cancer: potential for therapeutic intervention. Oncologist 8:5–17.
   PubMed Web of Science ®Google Scholar
• Nahta R, Yuan LX, Zhang B, et al. (2005). Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65:11118–28.
   PubMed Web of Science ®Google Scholar
• Rajah R, Valentinis B, Cohen P. (1997). Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272:12181–8.
   PubMed Web of Science ®Google Scholar
• Reginato MJ, Mills KR, Paulus JK, et al. (2003). Integrins and EGFR coordinately regulate the pro-apoptotic protein Bim to prevent anoikis. Nat Cell Biol 5:733–40.
   PubMed Web of Science ®Google Scholar
• Slamon DJ, Clark GM, Wong SG, et al. (1987). Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235:177–82.
   PubMed Web of Science ®Google Scholar
• Soutschek J, Akinc A, Bramlage B, et al. (2004). Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 432:173–8.
   PubMed Web of Science ®Google Scholar
• Stephen RL, Shaw LE, Larsen C, et al. (2001). Insulin-like growth factor receptor levels are regulated by cell density and by long term estrogen deprivation in MCF7 human breast cancer cells. J Biol Chem 276:40080–6.
   PubMed Web of Science ®Google Scholar
• Subik K, Lee JF, Baxter L, et al. (2010). The expression patterns of ER, PR, HER2, CK5/6, EGFR, Ki-67 and AR by immunohistochemical analysis in breast cancer cell lines. Breast Cancer (Auckl) 4:35–41.
   PubMedGoogle Scholar
• Tiash S, Othman I, Rosli R, Chowdhury EH. (2014). Methotrexate- and cyclophosphamide-embedded pure and strontiumsubstituted carbonate apatite nanoparticles for augmentation of chemotherapeutic activities in breast cancer cells. Curr Drug Deliv 11:214–22.
   PubMed Web of Science ®Google Scholar
• Ullrich A, Coussens L, Hayflick JS, et al. (1984). Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature 309:418–25.
   PubMed Web of Science ®Google Scholar
• Vickers TA, Lima WF, Nichols JG, Crooke ST. (2007). Reduced levels of Ago2 expression result in increased siRNA competition in mammalian cells. Nucleic Acids Res 35:6598–610.
   PubMed Web of Science ®Google Scholar
• Voldborg BR, Damstrup L, Spang-Thomsen M, Poulsen HS. (1997). Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 8:1197–206.
   PubMed Web of Science ®Google Scholar
• Waterfield MD. (1989). Growth factor receptors. Br Med Bull 45:541–53.
   PubMed Web of Science ®Google Scholar
• Xiong L, Kou F, Yang Y, Wu J. (2007). A novel role for IGF-1R in p53 mediated apoptosis through translational modulation of the p53-Mdm2 feedback loop. J Cell Biol 178:995–1007.
   PubMed Web of Science ®Google Scholar
• Yamamoto T, Ikawa S, Akiyama T, et al. (1986). Similarity of protein encoded by the human c-erb-B-2 gene to epidermal growth factor receptor. Nature 319:230–4.
   PubMed Web of Science ®Google Scholar
• Yarden Y. (2001). Biology of HER2 and its importance in breast cancer. Oncology 61:1–13.
   PubMed Web of Science ®Google Scholar
• Yarden Y. (2001). The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 37:S3–S8.
   PubMed Web of Science ®Google Scholar
• Yee D. (2002). The insulin-like growth factor system as a treatment target in breast cancer. Semin Oncol 29:86–95.
   PubMed Web of Science ®Google Scholar
• Yonesaka K, Zejnullahu K, Okamoto I, et al. (2011). Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. Sci Transl Med 3:99ra86
   PubMed Web of Science ®Google Scholar